Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess Treatment With PEG-Intron [peginterferon alfa-2b] and Rebetol [ribavirin] in Naive Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response.

Next Previous
X
Search
Trial Profile

A Study to Assess Treatment With PEG-Intron [peginterferon alfa-2b] and Rebetol [ribavirin] in Naive Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b/ribavirin (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms SUCCESS
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 16 May 2019 This trial has been completed in Spain as per European Clinical Trials Database record.
    • 27 Apr 2009 Final results presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009).
    • 31 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top